David S Boyer Selected Research

David S Boyer Research Topics

Disease

35	Macular Edema 01/2022 - 04/2004
32	Macular Degeneration (Age-Related Maculopathy) 05/2021 - 07/2002
17	Choroidal Neovascularization 05/2021 - 04/2004
11	Diabetic Retinopathy (Retinopathy, Diabetic) 04/2021 - 04/2004
9	Retinal Vein Occlusion 01/2018 - 03/2013
8	Inflammation (Inflammations) 04/2021 - 11/2006
4	Endophthalmitis (Ophthalmia) 01/2020 - 10/2006
4	Stroke (Strokes) 03/2015 - 11/2006
3	Edema (Dropsy) 04/2021 - 01/2014
3	Geographic Atrophy 01/2021 - 05/2017
3	Cataract (Cataracts) 10/2018 - 04/2012
3	Atrophy 10/2016 - 05/2015
2	Retinal Detachment (Retinal Detachments) 10/2020 - 12/2019
2	Low Vision (Subnormal Vision) 12/2019 - 04/2012
2	Retinal Perforations 01/2019 - 05/2015
2	Microaneurysm 01/2017 - 04/2004
2	Myocardial Infarction 04/2012 - 11/2006
1	Hypoxia (Hypoxemia) 04/2021
1	Vision Disorders (Hemeralopia) 04/2021
1	Ischemia 04/2021
1	Vascular Diseases (Vascular Disease) 01/2018
1	Choroidal Effusions 01/2018
1	Alzheimer Disease (Alzheimer's Disease) 08/2017
1	Amyloid Plaque 08/2017
1	Disease Progression 05/2015
1	Pneumonia (Pneumonitis) 03/2015
1	Vitreous Hemorrhage 07/2014
1	Osteoma 03/2014
1	Hemorrhage 03/2014
1	Melanoma (Melanoma, Malignant) 01/2014
1	Retinal Diseases 01/2014
1	Leiomyosarcoma 01/2014
1	Uveitis 10/2006
1	Cytomegalovirus Retinitis 04/2006
1	Acquired Immunodeficiency Syndrome (AIDS) 04/2006
1	Retinitis 04/2006
1	Central Serous Chorioretinopathy 06/2004
1	Epiretinal Membrane (Epiretinal Membranes) 12/2002
1	Glaucoma 10/2002

Drug/Important Bio-Agent (IBA)

22	afliberceptIBA 01/2022 - 03/2013
21	Ranibizumab (Lucentis)FDA Link 01/2020 - 10/2006
14	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 05/2021 - 10/2006
9	salicylhydroxamic acid (SHAM)IBA 05/2021 - 10/2006
9	Retinaldehyde (Retinal)IBA 12/2019 - 01/2014
9	Verteporfin (Visudyne)FDA Link 05/2012 - 04/2004
6	Mitochondrial DNA (mtDNA)IBA 08/2015 - 06/2009
5	1-phenyl-3,3-dimethyltriazene (PDT)IBA 05/2012 - 04/2004
4	Dexamethasone (Maxidex)FDA LinkGeneric 01/2018 - 05/2011
4	Complement System Proteins (Complement)IBA 05/2017 - 01/2014
4	Bevacizumab (Avastin)FDA Link 01/2017 - 04/2009
3	Fluorescein (Funduscein)FDA LinkGeneric 05/2021 - 04/2004
2	Adrenal Cortex Hormones (Corticosteroids)IBA 04/2021 - 07/2009
2	Triamcinolone Acetonide (Azmacort)FDA LinkGeneric 01/2018 - 01/2018
2	Endothelial Growth FactorsIBA 10/2016 - 07/2009
1	Amine Oxidase (Copper-Containing)IBA 04/2021
1	Reactive Oxygen Species (Oxygen Radicals)IBA 04/2021
1	Brimonidine Tartrate (Alphagan)FDA LinkGeneric 01/2021
1	risuteganibIBA 01/2021
1	Vascular Endothelial Growth FactorsIBA 01/2020
1	Complement C3 (C3 Complement)IBA 01/2020
1	pegcetacoplanIBA 01/2020
1	Plasma KallikreinIBA 12/2019
1	Antihypertensive Agents (Antihypertensives)IBA 12/2019
1	Pharmaceutical PreparationsIBA 10/2018
1	Triamcinolone (Aristocort)FDA Link 01/2018
1	CurcuminIBA 08/2017
1	Amyloid (Amyloid Fibrils)IBA 08/2017
1	LipidsIBA 08/2017
1	Biological ProductsIBA 03/2015
1	AKB-9778IBA 03/2015
1	Class 3 Receptor-Like Protein Tyrosine PhosphatasesIBA 03/2015
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 07/2009
1	Antisense OligonucleotidesIBA 07/2009
1	Diclofenac (SR 38)FDA LinkGeneric 07/2007
1	Tyrosine (L-Tyrosine)FDA Link 07/2007
1	Complement Factor H (Factor H)IBA 07/2007
1	Histidine (L-Histidine)FDA Link 07/2007
1	Monoclonal AntibodiesIBA 10/2006
1	Ganciclovir (Cytovene)FDA LinkGeneric 04/2006
1	Silicone OilsIBA 10/2002
1	DNA (Deoxyribonucleic Acid)IBA 07/2002

Therapy/Procedure

18	Lasers (Laser) 01/2019 - 04/2004
13	Therapeutics 01/2019 - 04/2005
11	Light Coagulation 10/2018 - 04/2004
8	Injections 04/2021 - 10/2006
8	Vitrectomy 10/2020 - 10/2002
7	Photochemotherapy (Photodynamic Therapy) 05/2012 - 04/2004
3	Intravitreal Injections 12/2019 - 10/2006
1	Drug Therapy (Chemotherapy) 04/2021
1	Traction 05/2015
1	Brachytherapy 01/2014